Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype

Clinical Cancer Research

Volumn 8, Issue 9, 2002, Pages 2894-2901

  Choe, Gheeyoung ^a   Park, Jun K ^a   Jouben Steele, Lisa ^a   Kremen, Thomas J ^a   Liau, Linda M ^a   Vinters, Harry V ^a   Cloughesy, Timothy F ^a   Mischel, Paul S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RECEPTOR SUBTYPE;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN METASTASIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE; ZYMOGRAPHY;

ADULT; AGED; BRAIN NEOPLASMS; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENES, P53; GLIOBLASTOMA; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036715324     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5
2. Matrix metalloproteinases: They're not just for matrix anymore!
3. Metalloproteinase-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor
4. Malignant glioma biology: Role for TGF-β in growth, motility, angiogenesis, and immune escape
5. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
6. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors
7. Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumors
8. Expression of matrix metalloproteinases and their inhibitors in human brain tumors
9. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MTI-MMP) are involved in different aspects of the pathophysiology of malignant gliomas
10. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas
11. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors
12. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro
13. r 92,000 type IV collagenase in human brain tumors
14. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors
15. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion
16. Matrix metalloproteinase-2 activation modulates glioma cell migration
17. The effect of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells
18. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo
19. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors
20. High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma
21. Primary and secondary glioblastomas: From concept to clinical diagnosis
22. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme
23. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
24. Analysis of genomic rearrangements associated with EGFRvIII expression suggests involvement of Alu repeat elements
25. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor. EGFRvIII
26. Aberrant receptor signaling in human malignant gliomas: Mechanisms and therapeutic implications
27. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas
28. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
29. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells
30. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer
31. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands
32. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion
33. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase-9 in head and neck squamous carcinoma cells
34. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association
35. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients
36. p21 and p53 in ovarian carcinoma: Their combined staining is more valuable than either alone
37. Activation of extracellular-regulated kinases by normal and mutant EGF receptors
38. Epidemiology
39. Molecular determinants of glioma cell migration and invasion
40. Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades
41. r 92,000 type IV collagenase during tumor growth in vivo
42. Effect of synthetic matrixmetalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro
43. Glioma invasion in vitro: Regulation by matrix metalloprotease-2 and protein kinase C
44. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2
45. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)
46. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloprotease-9 induction and cell migration
47. r 92,000 type IV collagenase secretion and in vitro invasion
48. Activation of matrix metalloprotease-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion
49. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloprotease-9 and mobilization of vascular endothelial growth factor